Johnson & Johnson (NYSE:JNJ) Shares Sold by Fiera Capital Corp

Key Points

• Fiera Capital Corp reduced its stake in Johnson & Johnson by 6.9% during the first quarter, now holding approximately 2.9 million shares worth nearly $483 million.
• Analysts have set various price targets for Johnson & Johnson, with UBS Group raising their target from $180.00 to $190.00, emphasizing a "buy" rating.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, representing a 3.13% dividend yield for shareholders.

Fiera Capital Corp lessened its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,913,416 shares of the company's stock after selling 214,303 shares during the quarter. Johnson & Johnson accounts for 1.7% of Fiera Capital Corp's investment portfolio, making the stock its 17th biggest position. Fiera Capital Corp owned 0.12% of Johnson & Johnson worth $483,161,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of JNJ. Brighton Jones LLC lifted its stake in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Hudson Value Partners LLC increased its holdings in Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after buying an additional 1,022 shares during the last quarter. WINTON GROUP Ltd bought a new stake in Johnson & Johnson in the fourth quarter valued at about $279,000. New Age Alpha Advisors LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at about $665,000. Finally, Prevail Innovative Wealth Advisors LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at about $209,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Raymond James Financial lowered their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. UBS Group boosted their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Finally, Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Stock Performance

JNJ stock traded up $2.73 on Friday, reaching $167.47. The company's stock had a trading volume of 4,303,979 shares, compared to its average volume of 9,042,880. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a market capitalization of $403.31 billion, a P/E ratio of 17.89, a price-to-earnings-growth ratio of 2.13 and a beta of 0.41. The firm has a fifty day moving average of $157.18 and a two-hundred day moving average of $156.44. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the company posted $2.82 EPS. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.